Introducere
Această pagină oferă o analiză cuprinzătoare a istoricului cunoscut al tranzacțiilor privilegiate a Mark N Lampert. Insiders sunt ofițeri, directori sau investitori importanți într-o companie. Este ilegal ca persoanele din interior să facă tranzacții în companiile lor pe baza unor informații specifice, nepublice. Acest lucru nu înseamnă că este ilegal pentru ei să facă tranzacții în propriile companii. Cu toate acestea, ei trebuie să raporteze toate tranzacțiile către SEC printr-un Formular 4. În ciuda acestor restricții, cercetările academice sugerează că persoanele din interior - în general - tind să depășească piața în propriile companii.
Rentabilitatea medie comercială
Rentabilitatea medie a comerțului este randamentul mediu al tuturor achizițiilor de pe piața deschisă efectuate de persoane din interior în ultimii trei ani. Pentru a calcula acest lucru, examinăm fiecare achiziție neplanificată pe piață deschisă făcută de către insider, excluzând toate tranzacțiile care au fost marcate ca parte a unui plan de tranzacționare 10b5-1. Apoi calculăm performanța medie a acelor tranzacții pe 3, 6 și 12 luni, făcând o medie a fiecărei durate pentru a genera o valoare finală a performanței pentru fiecare tranzacție. În cele din urmă, facem o medie a tuturor valorilor de performanță pentru a calcula o valoare de performanță pentru persoana din interior. Această listă include doar persoane din interior care au efectuat cel puțin trei tranzacții în ultimii doi ani.
Dacă profitabilitatea acestei tranzacții este „N/A”, atunci acesta fie nu a făcut nicio achiziție pe piața deschisă în ultimii trei ani, fie tranzacțiile pe care le-au făcut sunt prea recente pentru a calcula o măsură de performanță fiabilă.
Frecvența actualizării: zilnic
Consultați lista celor mai profitabili comercianți din interior.
Companii cu poziții din interior raportate
Înregistrările SEC indică faptul că Mark N Lampert a raportat participații sau tranzacții în următoarele companii:
Cum se interpretează diagramele
Următoarele diagrame arată performanța acțiunilor de valori mobiliare ulterioare fiecărei tranzacții neplanificate pe piață deschisă efectuată de Mark N Lampert. Comerțurile neplanificate sunt tranzacții care nu au fost efectuate ca parte a unui plan de tranzacționare 10b5-1. Performanța acțiunilor este reprezentată ca variație procentuală cumulată a prețului acțiunilor. De exemplu, dacă o tranzacție privilegiată a fost efectuată la 1 ianuarie 2019, graficul va afișa modificarea procentuală zilnică a titlului până în prezent. Dacă prețul acțiunilor ar merge de la 10 USD la 15 USD în acest timp, modificarea procentuală cumulativă a prețului acțiunilor ar fi de 50%. O modificare a prețului de la 10 USD la 20 USD ar fi 100%, iar o modificare a prețului de la 10 USD la 5 USD ar fi -50%.
În cele din urmă, încercăm să determinăm cât de strâns se corelează tranzacțiile insider-ului cu randamentele în exces (pozitive sau negative) ale prețului acțiunilor, pentru a vedea dacă insider-ul își programează tranzacțiile pentru a profita de informațiile privilegiate. Luați în considerare situația în care un insider făcea asta. În această situație, ne-am aștepta fie la (a) randamente pozitive după achiziții, fie (b) la profituri negative după vânzare. În cazul punctului (a), graficul CUMPĂRĂRI ar arăta o serie de curbe în pantă ascendentă, indicând randamente pozitive după fiecare tranzacție de cumpărare. În cazul (b), graficul VÂNZARE ar arăta o serie de curbe înclinate în jos, indicând randamente negative după fiecare tranzacție de vânzare.
Cu toate acestea, acest lucru în sine nu este suficient pentru a trage concluzii. Dacă, de exemplu, prețul acțiunilor companiei a fost într-o creștere neciclică de-a lungul multor ani, atunci ne-am aștepta ca toate parcelele post-cumpărare să fie în pantă ascendentă. De asemenea, scăderile non-ciclice de-a lungul multor ani ar avea ca rezultat o pantă descendentă post-tranzacționare. Niciunul dintre aceste grafice nu ar sugera activitate de tranzacționare a informațiilor privilegiate.
Cel mai puternic indicator ar fi o situație în care prețul acțiunilor a fost extrem de ciclic, și au existat atât semnale pozitive în graficul CUMPĂRARE, cât și grafice negative pe graficul VÂNZARE. Această situație ar sugera foarte mult un insider care a programat tranzacțiile în avantajul lor financiar.
Achiziții din interior CALA / Calithera Biosciences, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior CALA / Calithera Biosciences, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior CAPS / Capstone Holding Corp. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Max |
Pret la Max |
Max Profit ($) |
Randament maxim (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior CAPS / Capstone Holding Corp. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior CGEM / Cullinan Therapeutics, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior CGEM / Cullinan Therapeutics, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior CTMX / CytomX Therapeutics, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Max |
Pret la Max |
Max Profit ($) |
Randament maxim (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior CTMX / CytomX Therapeutics, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior CYTK / Cytokinetics, Incorporated - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior CYTK / Cytokinetics, Incorporated - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior ELDN / Eledon Pharmaceuticals, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior ELDN / Eledon Pharmaceuticals, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior FDMT / 4D Molecular Therapeutics, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Max |
Pret la Max |
Max Profit ($) |
Randament maxim (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior FDMT / 4D Molecular Therapeutics, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Max |
Pret la Max |
Max Profit ($) |
Randament maxim (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior IDYA / IDEAYA Biosciences, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior IDYA / IDEAYA Biosciences, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior IMUX / Immunic, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Max |
Pret la Max |
Max Profit ($) |
Randament maxim (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior IMUX / Immunic, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior INFIQ / Infinity Pharmaceuticals, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior INFIQ / Infinity Pharmaceuticals, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior KYMR / Kymera Therapeutics, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior KYMR / Kymera Therapeutics, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior MLTX / MoonLake Immunotherapeutics - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Max |
Pret la Max |
Max Profit ($) |
Randament maxim (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior MLTX / MoonLake Immunotherapeutics - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior OLMA / Olema Pharmaceuticals, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior OLMA / Olema Pharmaceuticals, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior RIGL / Rigel Pharmaceuticals, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior RIGL / Rigel Pharmaceuticals, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior SNDX / Syndax Pharmaceuticals, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Max |
Pret la Max |
Max Profit ($) |
Randament maxim (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior SNDX / Syndax Pharmaceuticals, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior VSTM / Verastem, Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Max |
Pret la Max |
Max Profit ($) |
Randament maxim (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior VSTM / Verastem, Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior XENE / Xenon Pharmaceuticals Inc. - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior XENE / Xenon Pharmaceuticals Inc. - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
| Data tranzacției | Ticker | Insider | Raportat Acțiuni |
Raportat Preț |
Ajustat Acțiuni |
Ajustat Preț |
Baza costurilor | Zile pentru Min |
Pret la Min |
Pierdere maximă Evitat ($) |
Pierdere maximă Evitat (%) |
|---|---|---|---|---|---|---|---|
| Nu se cunosc tranzacții neplanificate pe piața deschisă pentru această combinație de informații privilegiate și de securitate |
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Achiziții din interior XOMAO / XOMA Royalty Corporation - Preferred Stock - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Vânzări din interior XOMAO / XOMA Royalty Corporation - Preferred Stock - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în CALA / Calithera Biosciences, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție, iar rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate sunt acțiunile ajustate în funcție de divizarea.
Istoricul tranzacțiilor privilegiate
Acest tabel arată lista completă a tranzacțiilor privilegiate efectuate de Mark N Lampert, astfel cum a fost dezvăluită Comisiei pentru Bursa de Valori Valori (SEC).
| Data fișierului | Tran Data | Formă | Ticker | Securitate | Cod | Acțiuni | Acțiuni rămase | La sută Schimbare |
Acțiune Preț |
Tran Valoare |
Rămas Valoare |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 772.000 | 772.000 | 4,03 | 3.111.160 | 3.111.160 | ||
| 2026-05-18 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 412.000 | 412.000 | 4,03 | 1.660.360 | 1.660.360 | ||
| 2026-05-18 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 1.506.000 | 2.773.545 | 118,81 | 4,03 | 6.069.180 | 11.177.386 | |
| 2026-05-18 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 2.313.000 | 3.635.758 | 174,86 | 4,03 | 9.321.390 | 14.652.105 | |
| 2026-04-02 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -248.530 | 1.039.238 | -19,30 | 16,79 | -4.172.819 | 17.448.806 | |
| 2026-04-02 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1.569.116 | 6.599.722 | -19,21 | 16,79 | -26.345.458 | 110.809.332 | |
| 2026-04-02 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1.932.354 | 8.302.735 | -18,88 | 16,79 | -32.444.224 | 139.402.921 | |
| 2026-02-27 | 3 | IMUX |
IMMUNIC, INC.
Common Stock, $0.0001 par value |
4.135.956 | ||||||||
| 2026-02-27 | 3 | IMUX |
IMMUNIC, INC.
Common Stock, $0.0001 par value |
3.027.105 | ||||||||
| 2026-02-27 | 3 | IMUX |
IMMUNIC, INC.
Common Stock, $0.0001 par value |
427.629 | ||||||||
| 2026-01-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
U - Other | -548.938 | 0 | -100,00 | ||||
| 2026-01-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
U - Other | -4.308.573 | 0 | -100,00 | ||||
| 2026-01-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
U - Other | -5.309.432 | 0 | -100,00 | ||||
| 2025-10-14 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
U - Other | -560.797 | 0 | -100,00 | ||||
| 2025-10-14 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
U - Other | -4.726.743 | 0 | -100,00 | ||||
| 2025-10-14 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
U - Other | -6.194.145 | 0 | -100,00 | ||||
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -11 | 560.797 | 0,00 | 1,88 | -21 | 1.053.121 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -66 | 4.726.743 | 0,00 | 1,88 | -124 | 8.876.351 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -79 | 6.194.145 | 0,00 | 1,88 | -148 | 11.631.985 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 203.336 | 560.808 | 56,88 | 0,00 | 20 | 56 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1.235.030 | 4.726.809 | 35,37 | 0,00 | 124 | 473 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1.481.634 | 6.194.224 | 31,44 | 0,00 | 148 | 619 | |
| 2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58.780 | 353.412 | 19,95 | 44,00 | 2.586.320 | 15.550.128 | |
| 2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 115.783 | 2.219.858 | 5,50 | 44,00 | 5.094.452 | 97.673.752 | |
| 2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 142.604 | 2.798.795 | 5,37 | 44,00 | 6.274.576 | 123.146.980 | |
| 2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 56.079 | 62.383 | 889,58 | ||||
| 2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 556.617 | 593.740 | 1.499,39 | ||||
| 2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 657.308 | 707.116 | 1.319,68 | ||||
| 2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -265.316 | 1.267.545 | -17,31 | 27,10 | -7.190.064 | 34.350.470 | |
| 2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -127.407 | 1.322.758 | -8,79 | 27,10 | -3.452.730 | 35.846.742 | |
| 2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -855.211 | 0 | -100,00 | ||||
| 2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -6.777.935 | 0 | -100,00 | ||||
| 2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -8.679.726 | 0 | -100,00 | ||||
| 2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -149.975 | 0 | -100,00 | 26,10 | -3.914.348 | ||
| 2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -75.287 | 0 | -100,00 | 26,10 | -1.964.991 | ||
| 2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -85.776 | 1.532.861 | -5,30 | 26,10 | -2.238.754 | 40.007.672 | |
| 2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -339.679 | 1.450.165 | -18,98 | 26,10 | -8.865.622 | 37.849.306 | |
| 2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -22.740 | 347.970 | -6,13 | ||||
| 2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -161.810 | 2.003.966 | -7,47 | ||||
| 2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -235.450 | 2.655.977 | -8,14 | ||||
| 2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 29.648 | 38.961 | 318,35 | ||||
| 2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 174.958 | 282.223 | 163,11 | ||||
| 2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 234.323 | 371.916 | 170,30 | ||||
| 2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -153.441 | 370.710 | -29,27 | ||||
| 2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1.418.736 | 2.165.776 | -39,58 | ||||
| 2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1.797.527 | 2.891.427 | -38,34 | ||||
| 2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -240.000 | 87.911 | -73,19 | ||||
| 2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -2.378.000 | 662.970 | -78,20 | ||||
| 2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -3.062.000 | 830.237 | -78,67 | ||||
| 2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -64.617 | 176.692 | -26,78 | 14,30 | -924.023 | 2.526.696 | |
| 2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -396.963 | 1.367.257 | -22,50 | 14,30 | -5.676.571 | 19.551.775 | |
| 2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -538.420 | 1.794.218 | -23,08 | 14,30 | -7.699.406 | 25.657.317 | |
| 2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -132.549 | 1.287.768 | -9,33 | 50,00 | -6.627.662 | 64.390.460 | |
| 2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -836.862 | 8.168.838 | -9,29 | 50,00 | -41.844.439 | 408.454.970 | |
| 2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1.030.589 | 10.235.089 | -9,15 | 50,00 | -51.531.099 | 511.770.826 | |
| 2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3.892.237 | ||||||||
| 2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3.040.970 | ||||||||
| 2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
327.911 | ||||||||
| 2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 75.431 | 220.460 | 52,01 | ||||
| 2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 821.121 | 2.633.679 | 45,30 | ||||
| 2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.031.385 | 3.361.803 | 44,26 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -341.547 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -185.388 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2.076.085 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1.367.838 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2.870.985 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1.734.960 | 0 | -100,00 | ||||
| 2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
8.679.726 | ||||||||
| 2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
6.777.935 | ||||||||
| 2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
855.211 | ||||||||
| 2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -896.366 | 0 | -100,00 | 12,45 | -11.159.757 | ||
| 2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -7.290.667 | 0 | -100,00 | 12,45 | -90.768.804 | ||
| 2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -8.974.245 | 0 | -100,00 | 12,45 | -111.729.350 | ||
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 16.143 | 548.938 | 3,03 | 5,38 | 86.909 | 2.955.318 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 125.909 | 4.308.573 | 3,01 | 5,38 | 677.856 | 23.196.064 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 153.693 | 5.309.432 | 2,98 | 5,38 | 827.437 | 28.584.389 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 47.712 | 532.795 | 9,84 | 5,00 | 238.555 | 2.663.922 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 390.507 | 4.182.664 | 10,30 | 5,00 | 1.952.496 | 20.912.902 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 493.337 | 5.155.739 | 10,58 | 5,00 | 2.466.636 | 25.778.179 | |
| 2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
1.204.412 | ||||||||
| 2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
912.776 | ||||||||
| 2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
104.257 | ||||||||
| 2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
8.974.245 | ||||||||
| 2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
7.290.667 | ||||||||
| 2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
896.366 | ||||||||
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.106 | 294.632 | 3,55 | 14,07 | 142.180 | 4.145.148 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 83.708 | 2.104.075 | 4,14 | 14,07 | 1.177.679 | 29.602.021 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 103.885 | 2.656.191 | 4,07 | 14,07 | 1.461.548 | 37.369.686 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26.772 | 284.526 | 10,39 | 11,64 | 311.744 | 3.313.135 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 132.016 | 2.020.367 | 6,99 | 11,64 | 1.537.247 | 23.525.961 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57.618 | 2.552.306 | 2,31 | 11,64 | 670.927 | 29.720.072 | |
| 2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 72.479 | 485.083 | 17,57 | 3,60 | 260.924 | 1.746.299 | |
| 2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 492.251 | 3.792.157 | 14,92 | 3,60 | 1.772.104 | 13.651.765 | |
| 2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 218.979 | 4.662.402 | 4,93 | 3,60 | 788.324 | 16.784.647 | |
| 2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99.556 | 99.556 | |||||
| 2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 52.801 | 524.151 | 11,20 | 9,84 | 519.562 | 5.157.646 | |
| 2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 677.853 | 3.584.512 | 23,32 | 9,84 | 6.670.074 | 35.271.598 | |
| 2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 775.278 | 4.688.954 | 19,81 | 9,84 | 7.628.736 | 46.139.307 | |
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -43.139 | 0 | -100,00 | 9,10 | -392.565 | ||
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -1.526.147 | 0 | -100,00 | 9,10 | -13.887.938 | ||
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -702.505 | 0 | -100,00 | 9,10 | -6.392.796 | ||
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -2.595.239 | 0 | -100,00 | 9,10 | -23.616.675 | ||
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -3.989.130 | 0 | -100,00 | 9,10 | -36.301.083 | ||
| 2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
11.007.420 | ||||||||
| 2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
8.581.171 | ||||||||
| 2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
744.966 | ||||||||
| 2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -462.605 | 0 | -100,00 | ||||
| 2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -2.929.660 | 0 | -100,00 | ||||
| 2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -4.018.253 | 0 | -100,00 | ||||
| 2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 86.341 | 145.029 | 147,12 | ||||
| 2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 837.146 | 1.812.558 | 85,82 | ||||
| 2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.055.445 | 2.330.418 | 82,78 | ||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
4.018.253 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2.801.529 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2.929.660 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2.130.657 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
462.605 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
241.755 | ||||||||
| 2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -300.000 | 64.161 | -82,38 | ||||
| 2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -2.600.000 | 392.808 | -86,87 | ||||
| 2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -3.500.000 | 558.854 | -86,23 | ||||
| 2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 15.912 | 1.888.351 | 0,85 | 31,24 | 497.132 | 58.996.995 | |
| 2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 2.985 | 2.494.688 | 0,12 | 31,24 | 93.259 | 77.940.539 | |
| 2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11.149 | 1.872.439 | 0,60 | 29,89 | 333.209 | 55.961.397 | |
| 2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.961 | 2.491.703 | 0,44 | 29,89 | 327.590 | 74.469.278 | |
| 2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.573 | 1.618.637 | 0,10 | 21,98 | 34.577 | 35.580.393 | |
| 2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.676 | 1.789.844 | 0,09 | 21,98 | 36.841 | 39.343.814 | |
| 2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 15.670 | 1.617.064 | 0,98 | 18,39 | 288.096 | 29.730.045 | |
| 2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.330 | 1.788.168 | 0,19 | 18,39 | 61.223 | 32.875.826 | |
| 2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 9.597 | 241.309 | 4,14 | 4,11 | 39.430 | 991.442 | |
| 2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 87.831 | 1.764.220 | 5,24 | 4,11 | 360.862 | 7.248.474 | |
| 2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 116.635 | 2.332.638 | 5,26 | 4,11 | 479.207 | 9.583.876 | |
| 2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
2.216.003 | ||||||||
| 2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
1.676.389 | ||||||||
| 2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
231.712 | ||||||||
| 2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 54.857 | 341.547 | 19,13 | 5,83 | 319.816 | 1.991.219 | |
| 2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 685.330 | 2.076.085 | 49,28 | 5,83 | 3.995.474 | 12.103.576 | |
| 2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 970.171 | 2.870.985 | 51,04 | 5,83 | 5.656.097 | 16.737.843 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 678 | 1.601.394 | 0,04 | 16,89 | 11.452 | 27.047.865 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.004 | 1.784.838 | 0,06 | 16,89 | 16.958 | 30.146.271 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.021 | 1.600.716 | 0,19 | 16,83 | 50.849 | 26.942.771 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.339 | 1.783.834 | 0,19 | 16,83 | 56.201 | 30.024.959 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.885 | 1.597.695 | 0,62 | 16,50 | 163.073 | 26.357.174 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6.715 | 1.780.495 | 0,38 | 16,50 | 110.777 | 29.372.826 | |
| 2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13.396 | 1.773.780 | 0,76 | 17,89 | 239.618 | 31.728.135 | |
| 2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.897 | 1.587.810 | 0,69 | 17,89 | 194.918 | 28.401.634 | |
| 2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5.575 | 1.576.913 | 0,35 | 17,96 | 100.138 | 28.324.511 | |
| 2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 26.441 | 1.571.338 | 1,71 | 17,25 | 456.044 | 27.101.809 | |
| 2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27.117 | 257.754 | 11,76 | 26,00 | 705.042 | 6.701.604 | |
| 2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 233.362 | 1.861.290 | 14,33 | 26,00 | 6.067.412 | 48.393.540 | |
| 2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 285.046 | 2.480.742 | 12,98 | 26,00 | 7.411.196 | 64.499.292 | |
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 1.519.999 | 1.526.147 | 24.723,47 | ||||
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -1.289.434 | 6.148 | -99,53 | 6,12 | -7.891.336 | 37.626 | |
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 682.666 | 702.505 | 3.441,03 | ||||
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -469.040 | 19.839 | -95,94 | 6,12 | -2.870.525 | 121.415 | |
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 2.426.666 | 2.595.239 | 1.439,53 | ||||
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -2.890.723 | 168.573 | -94,49 | 6,12 | -17.691.225 | 1.031.667 | |
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 3.754.000 | 3.989.130 | 1.596,56 | ||||
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -3.850.803 | 235.130 | -94,25 | 6,12 | -23.566.914 | 1.438.996 | |
| 2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
4.712.590 | ||||||||
| 2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
3.491.779 | ||||||||
| 2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
357.472 | ||||||||
| 2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
2.132.411 | ||||||||
| 2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
1.570.857 | ||||||||
| 2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
209.716 | ||||||||
| 2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 6.168 | 412.604 | 1,52 | 12,73 | 78.519 | 5.252.449 | |
| 2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 68.327 | 3.299.906 | 2,11 | 12,73 | 869.803 | 42.007.803 | |
| 2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 74.666 | 4.443.423 | 1,71 | 12,73 | 950.498 | 56.564.775 | |
| 2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 41.417 | 2.906.659 | 1,45 | 4,03 | 167.097 | 11.726.916 | |
| 2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 158.583 | 3.913.676 | 4,22 | 4,03 | 639.803 | 15.789.726 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 20 | 406.436 | 0,00 | 13,21 | 264 | 5.369.751 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3.040 | 3.231.579 | 0,09 | 13,21 | 40.164 | 42.694.975 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3.809 | 4.368.757 | 0,09 | 13,21 | 50.324 | 57.719.144 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 31.903 | 406.416 | 8,52 | 12,29 | 391.960 | 4.993.227 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 258.797 | 3.228.539 | 8,71 | 12,29 | 3.179.580 | 39.665.830 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 353.344 | 4.364.948 | 8,81 | 12,29 | 4.341.184 | 53.627.751 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 61.156 | 374.513 | 19,52 | 11,68 | 714.449 | 4.375.211 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 464.235 | 2.969.742 | 18,53 | 11,68 | 5.423.379 | 34.693.714 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 660.654 | 4.011.604 | 19,72 | 11,68 | 7.718.024 | 46.865.163 | |
| 2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 44.746 | 364.161 | 14,01 | 11,00 | 492.179 | 4.005.553 | |
| 2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 301.009 | 2.992.808 | 11,18 | 11,00 | 3.310.918 | 32.919.092 | |
| 2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 405.641 | 4.058.854 | 11,10 | 11,00 | 4.461.808 | 44.644.959 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 3.223 | 230.637 | 1,42 | 14,78 | 47.645 | 3.409.461 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26.353 | 1.627.928 | 1,65 | 14,78 | 389.571 | 24.065.334 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 35.793 | 2.195.696 | 1,66 | 14,78 | 529.121 | 32.458.535 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.642 | 227.414 | 4,91 | 14,21 | 151.229 | 3.231.689 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 90.372 | 1.601.575 | 5,98 | 14,21 | 1.284.240 | 22.759.342 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 123.043 | 2.159.903 | 6,04 | 14,21 | 1.748.515 | 30.693.518 | |
| 2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37 | 216.772 | 0,02 | 14,00 | 518 | 3.034.678 | |
| 2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4.180 | 1.511.203 | 0,28 | 14,00 | 58.517 | 21.155.935 | |
| 2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 5.883 | 2.036.860 | 0,29 | 14,00 | 82.358 | 28.514.818 | |
| 2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 5.730 | 313.357 | 1,86 | 8,50 | 48.705 | 2.663.534 | |
| 2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 189.882 | 2.505.507 | 8,20 | 8,50 | 1.613.997 | 21.296.810 | |
| 2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 224.388 | 3.350.950 | 7,18 | 8,50 | 1.907.298 | 28.483.075 | |
| 2022-05-20 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 8.996 | 8.996 | |||||
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 17.744 | 319.415 | 5,88 | 9,14 | 162.091 | 2.917.856 | |
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 38.558 | 2.691.799 | 1,45 | 9,14 | 352.227 | 24.589.584 | |
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 53.598 | 3.653.213 | 1,49 | 9,14 | 489.618 | 33.372.101 | |
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 457.001 | 2.653.241 | 20,81 | 9,06 | 4.140.429 | 24.038.363 | |
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 542.999 | 3.599.615 | 17,76 | 9,06 | 4.919.571 | 32.612.512 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4.131 | 216.735 | 1,94 | 19,26 | 79.542 | 4.173.232 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 40.659 | 1.507.023 | 2,77 | 19,26 | 782.889 | 29.017.728 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 55.210 | 2.030.977 | 2,79 | 19,26 | 1.063.069 | 39.106.462 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4.066 | 212.604 | 1,95 | 19,60 | 79.690 | 4.166.847 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 70.439 | 1.466.364 | 5,05 | 19,60 | 1.380.541 | 28.739.415 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 75.495 | 1.975.767 | 3,97 | 19,60 | 1.479.634 | 38.723.255 | |
| 2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
11.265.678 | ||||||||
| 2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
9.005.699 | ||||||||
| 2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
1.420.317 | ||||||||
| 2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 9.402 | 2.196.240 | 0,43 | 10,75 | 101.071 | 23.609.360 | |
| 2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 266.598 | 3.056.616 | 9,56 | 10,75 | 2.865.902 | 32.858.316 | |
| 2022-03-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80.000 | 80.000 | |||||
| 2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
10.753.294 | ||||||||
| 2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
7.883.287 | ||||||||
| 2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
994.353 | ||||||||
| 2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14.323 | 1.395.925 | 1,04 | 40,70 | 582.946 | 56.814.148 | |
| 2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 20.085 | 1.900.272 | 1,07 | 40,70 | 817.460 | 77.341.070 | |
| 2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37.859 | 1.381.602 | 2,82 | 38,33 | 1.451.207 | 52.959.430 | |
| 2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58.042 | 1.880.187 | 3,19 | 38,33 | 2.224.860 | 72.071.140 | |
| 2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
1.274.973 | ||||||||
| 2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
975.412 | ||||||||
| 2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
58.688 | ||||||||
| 2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 114.726 | 1.343.743 | 9,33 | 37,76 | 4.332.455 | 50.744.439 | |
| 2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 158.041 | 1.822.145 | 9,50 | 37,76 | 5.968.181 | 68.810.573 | |
| 2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 7.899 | 307.627 | 2,64 | 14,10 | 111.376 | 4.337.541 | |
| 2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 412.264 | 2.315.625 | 21,66 | 14,10 | 5.812.922 | 32.650.312 | |
| 2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 577.798 | 3.126.562 | 22,67 | 14,10 | 8.146.952 | 44.084.524 | |
| 2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2.790.018 | ||||||||
| 2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2.186.838 | ||||||||
| 2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
301.671 | ||||||||
| 2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14.806 | 185.388 | 8,68 | 12,00 | 177.672 | 2.224.656 | |
| 2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 226.079 | 1.367.838 | 19,80 | 12,00 | 2.712.948 | 16.414.056 | |
| 2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 255.500 | 1.734.960 | 17,27 | 12,00 | 3.066.000 | 20.819.520 | |
| 2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 61.343 | 1.141.759 | 5,68 | 12,00 | 736.018 | 13.699.281 | |
| 2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 35.268 | 471.350 | 8,09 | 9,39 | 331.177 | 4.426.118 | |
| 2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 341.977 | 2.865.242 | 13,55 | 9,39 | 3.211.267 | 26.905.482 | |
| 2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 362.430 | 3.755.093 | 10,68 | 9,39 | 3.403.326 | 35.261.450 | |
| 2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
2.548.764 | ||||||||
| 2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
1.903.361 | ||||||||
| 2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
299.728 | ||||||||
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -8.929 | 232.747 | -3,69 | 27,79 | -248.106 | 6.467.225 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -58.327 | 1.520.405 | -3,69 | 27,79 | -1.620.703 | 42.246.734 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -80.011 | 2.085.664 | -3,69 | 27,79 | -2.223.226 | 57.953.303 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -69.534 | 241.676 | -22,34 | 27,53 | -1.914.348 | 6.653.606 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -384.914 | 1.578.732 | -19,60 | 27,53 | -10.597.106 | 43.464.229 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -530.999 | 2.165.675 | -19,69 | 27,53 | -14.618.987 | 59.623.415 | |
| 2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 590 | 170.582 | 0,35 | 13,94 | 8.226 | 2.378.357 | |
| 2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 4.102 | 1.080.416 | 0,38 | 13,94 | 57.193 | 15.063.808 | |
| 2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.341 | 1.479.460 | 0,43 | 13,94 | 88.410 | 20.627.519 | |
| 2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20.512 | 169.992 | 13,72 | 16,49 | 338.243 | 2.803.168 | |
| 2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 158.511 | 1.076.314 | 17,27 | 16,49 | 2.613.846 | 17.748.418 | |
| 2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 213.246 | 1.473.119 | 16,93 | 16,49 | 3.516.427 | 24.291.732 | |
| 2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -150.805 | 311.210 | -32,64 | 20,75 | -3.129.204 | 6.457.608 | |
| 2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -928.739 | 1.963.646 | -32,11 | 20,75 | -19.271.334 | 40.745.654 | |
| 2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -1.106.478 | 2.696.674 | -29,09 | 20,75 | -22.959.418 | 55.955.986 | |
| 2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27.458 | 208.538 | 15,16 | 47,00 | 1.290.526 | 9.801.286 | |
| 2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 211.711 | 1.229.017 | 20,81 | 47,00 | 9.950.417 | 57.763.799 | |
| 2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 304.997 | 1.664.104 | 22,44 | 47,00 | 14.334.859 | 78.212.888 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 16.980 | 149.480 | 12,82 | 15,25 | 258.945 | 2.279.570 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 106.627 | 917.803 | 13,14 | 15,25 | 1.626.062 | 13.996.496 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 146.116 | 1.259.873 | 13,12 | 15,25 | 2.228.269 | 19.213.063 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20.018 | 132.500 | 17,80 | 15,65 | 313.282 | 2.073.625 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 124.804 | 811.176 | 18,18 | 15,65 | 1.953.183 | 12.694.904 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 172.457 | 1.113.757 | 18,32 | 15,65 | 2.698.952 | 17.430.297 | |
| 2021-06-21 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 20.063 | 20.063 | |||||
| 2021-05-26 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99.556 | 99.556 | |||||
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 129 | 112.482 | 0,11 | 15,90 | 2.050 | 1.787.924 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 513 | 686.372 | 0,07 | 15,90 | 8.154 | 10.910.020 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 719 | 941.300 | 0,08 | 15,90 | 11.429 | 14.962.152 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 7.592 | 112.353 | 7,25 | 15,94 | 121.032 | 1.791.132 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 48.152 | 685.859 | 7,55 | 15,94 | 767.639 | 10.933.964 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 66.242 | 940.581 | 7,58 | 15,94 | 1.056.030 | 14.994.742 | |
| 2021-05-21 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 5.101 | 5.101 | |||||
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.115 | 104.761 | 1,08 | 15,88 | 17.711 | 1.664.055 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.962 | 637.707 | 1,10 | 15,88 | 110.586 | 10.129.529 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 9.191 | 874.339 | 1,06 | 15,88 | 145.993 | 13.888.263 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 11.946 | 103.646 | 13,03 | 16,65 | 198.901 | 1.725.706 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 75.640 | 630.745 | 13,63 | 16,65 | 1.259.406 | 10.501.904 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 103.611 | 865.148 | 13,61 | 16,65 | 1.725.123 | 14.404.714 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.747 | 88.226 | 2,02 | 14,90 | 26.032 | 1.314.647 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 10.876 | 532.384 | 2,09 | 14,90 | 162.062 | 7.933.001 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14.790 | 729.732 | 2,07 | 14,90 | 220.384 | 10.873.664 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.141 | 86.479 | 7,64 | 15,93 | 97.817 | 1.377.481 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 62.948 | 80.338 | 361,98 | 17,00 | 1.070.116 | 1.365.746 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 38.858 | 521.508 | 8,05 | 15,93 | 618.950 | 8.306.840 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 398.300 | 482.650 | 472,20 | 17,00 | 6.771.100 | 8.205.050 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 53.303 | 714.942 | 8,06 | 15,93 | 849.037 | 11.387.954 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 546.346 | 661.639 | 473,88 | 17,00 | 9.287.882 | 11.247.863 | |
| 2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.474 | 91.700 | 3,94 | 14,26 | 49.544 | 1.307.780 | |
| 2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 22.721 | 555.105 | 4,27 | 14,26 | 324.036 | 7.916.630 | |
| 2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 31.805 | 761.537 | 4,36 | 14,26 | 453.587 | 10.860.660 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 1.747 | 88.226 | 2,02 | 14,90 | 26.032 | 1.314.647 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 10.876 | 532.384 | 2,09 | 14,90 | 162.062 | 7.933.001 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 14.790 | 729.732 | 2,07 | 14,90 | 220.384 | 10.873.664 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -134.515 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -152.176 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -17.390 | 152.176 | -10,26 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -837.397 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -553.359 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -84.350 | 553.359 | -13,23 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.068.554 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -832.261 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -115.293 | 832.261 | -12,17 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 134.515 | 286.691 | 88,39 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 152.176 | 152.176 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 6.141 | 86.479 | 7,64 | 15,93 | 97.817 | 1.377.481 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 62.948 | 80.338 | 361,98 | 17,00 | 1.070.116 | 1.365.746 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 17.390 | 17.390 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 837.397 | 1.390.756 | 151,33 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 553.359 | 553.359 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 38.858 | 521.508 | 8,05 | 15,93 | 618.950 | 8.306.840 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 398.300 | 482.650 | 472,20 | 17,00 | 6.771.100 | 8.205.050 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 84.350 | 84.350 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 1.068.554 | 1.900.815 | 128,39 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 832.261 | 832.261 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 53.303 | 714.942 | 8,06 | 15,93 | 849.037 | 11.387.954 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 546.346 | 661.639 | 473,88 | 17,00 | 9.287.882 | 11.247.863 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 115.293 | 115.293 | |||||
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 17 | 17 | 25.000,00 | 425.000 | 425.000 | ||
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 239 | 239 | 25.000,00 | 5.975.000 | 5.975.000 | ||
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 344 | 344 | 25.000,00 | 8.600.000 | 8.600.000 | ||
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 5.171 | 488.879 | 1,07 | 2,50 | 12.928 | 1.222.198 | |
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 950.016 | 3.059.296 | 45,04 | 2,50 | 2.375.040 | 7.648.240 | |
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 1.044.813 | 4.085.933 | 34,36 | 2,50 | 2.612.032 | 10.214.832 | |
| 2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -81.903 | 149.975 | -35,32 | 38,36 | -3.141.799 | 5.753.041 | |
| 2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -84.250 | 75.287 | -52,81 | 38,36 | -3.231.830 | 2.888.009 | |
| 2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -205.807 | 1.544.897 | -11,76 | 38,36 | -7.894.757 | 59.262.249 | |
| 2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -279.740 | 1.760.384 | -13,71 | 38,36 | -10.730.826 | 67.528.330 | |
| 2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 26.894 | 462.015 | 6,18 | 19,75 | 531.156 | 9.124.796 | |
| 2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 108.106 | 2.892.385 | 3,88 | 19,75 | 2.135.094 | 57.124.604 | |
| 2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 165.000 | 3.803.152 | 4,54 | 19,75 | 3.258.750 | 75.112.252 | |
| 2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 7.744 | 435.121 | 1,81 | 22,75 | 176.176 | 9.899.003 | |
| 2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 71.756 | 3.638.152 | 2,01 | 22,75 | 1.632.449 | 82.767.958 | |
| 2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 1.171 | 427.377 | 0,27 | 23,00 | 26.933 | 9.829.500 | |
| 2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 195.768 | 2.784.279 | 7,56 | 23,00 | 4.502.586 | 64.037.303 | |
| 2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53.061 | 3.566.396 | 1,51 | 23,00 | 1.220.382 | 82.025.681 | |
| 2021-03-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80.000 | 80.000 | |||||
| 2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
3.372.098 | ||||||||
| 2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
2.484.643 | ||||||||
| 2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
405.344 | ||||||||
| 2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -152.127 | 534.847 | -22,14 | 5,37 | -816.709 | 2.871.380 | |
| 2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -892.467 | 3.279.831 | -21,39 | 5,37 | -4.791.298 | 17.608.101 | |
| 2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1.215.491 | 4.448.421 | -21,46 | 5,37 | -6.525.485 | 23.881.793 | |
| 2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -4.325 | 233.150 | -1,82 | 18,00 | -77.850 | 4.196.700 | |
| 2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -16.850 | 1.188.131 | -1,40 | 18,00 | -303.300 | 21.386.358 | |
| 2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -25.234 | 1.642.186 | -1,51 | 18,00 | -454.212 | 29.559.348 | |
| 2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -568.019 | 686.974 | -45,26 | 4,14 | -2.350.917 | 2.843.248 | |
| 2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2.458.838 | 4.172.298 | -37,08 | 4,14 | -10.176.639 | 17.268.307 | |
| 2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2.821.663 | 5.663.912 | -33,25 | 4,14 | -11.678.299 | 23.441.799 | |
| 2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 43.422 | 426.206 | 11,34 | 24,75 | 1.074.694 | 10.548.598 | |
| 2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 343.444 | 2.588.511 | 15,30 | 24,75 | 8.500.239 | 64.065.647 | |
| 2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 457.814 | 3.513.335 | 14,98 | 24,75 | 11.330.896 | 86.955.041 | |
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -1.757 | 6.758 | -20,63 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -9.169 | 39.693 | -18,77 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -11.776 | 52.145 | -18,42 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -35 | 0 | -100,00 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -203 | 0 | -100,00 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -273 | 0 | -100,00 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 97.615 | 113.152 | 628,27 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 1.944 | 15.537 | 14,30 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 509.410 | 598.624 | 571,00 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 11.278 | 89.214 | 14,47 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 654.215 | 771.780 | 556,47 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 15.166 | 117.565 | 14,81 | ||||
| 2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2.945.743 | ||||||||
| 2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2.164.406 | ||||||||
| 2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
358.450 | ||||||||
| 2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 45.032 | 2.245.067 | 2,05 | 16,05 | 722.764 | 36.033.325 | |
| 2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 114.968 | 3.055.521 | 3,91 | 16,05 | 1.845.236 | 49.041.112 | |
| 2020-12-15 |
|
4 | XOMA |
XOMA Corp
8.625% Series A Cumulative Perpetual Preferred Stock |
P - Purchase | 200.000 | 200.000 | 25,00 | 5.000.000 | 5.000.000 | ||
| 2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -25.486 | 463.244 | -5,21 | 18,00 | -458.748 | 8.338.392 | |
| 2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -166.194 | 2.760.185 | -5,68 | 18,00 | -2.991.492 | 49.683.330 | |
| 2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -239.274 | 3.811.271 | -5,91 | 18,00 | -4.306.932 | 68.602.878 | |
| 2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
4.050.545 | ||||||||
| 2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2.926.379 | ||||||||
| 2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
488.730 | ||||||||
| 2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -93 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -551 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -740 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -73.399 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -522.403 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -760.155 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -101.784 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -673.281 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -889.186 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -185.908 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -881.156 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -1.129.404 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 74.991 | 436.082 | 20,77 | 19,00 | 1.424.829 | 8.285.558 | |
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 73.399 | 361.091 | 25,51 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 101.784 | 287.692 | 54,75 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 185.908 | 185.908 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 446.425 | 2.523.265 | 21,50 | 19,00 | 8.482.075 | 47.942.035 | |
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 522.403 | 2.076.840 | 33,61 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 673.281 | 1.554.437 | 76,41 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 881.156 | 881.156 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 613.918 | 3.392.663 | 22,09 | 19,00 | 11.664.442 | 64.460.597 | |
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 760.155 | 2.778.745 | 37,66 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 889.186 | 2.018.590 | 78,73 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 1.129.404 | 1.129.404 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21.520 | 21.520 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21.520 | 21.520 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21.520 | 21.520 | |||||
| 2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
3.822.766 | ||||||||
| 2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2.777.320 | ||||||||
| 2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
465.924 | ||||||||
| 2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -502.649 | 81.263 | -86,08 | 20,19 | -10.146.825 | 1.640.432 | |
| 2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -2.949.477 | 485.513 | -85,87 | 20,19 | -59.540.207 | 9.800.905 | |
| 2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -3.941.214 | 670.695 | -85,46 | 20,19 | -79.560.105 | 13.539.119 | |
| 2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 86.090 | 630.453 | 15,81 | 2,60 | 223.834 | 1.639.178 | |
| 2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 506.155 | 3.712.350 | 15,79 | 2,60 | 1.316.003 | 9.652.110 | |
| 2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 674.492 | 4.980.812 | 15,66 | 2,60 | 1.753.679 | 12.950.111 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.334 | 583.912 | 0,40 | 4,98 | 11.633 | 2.910.217 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10.436 | 3.434.990 | 0,30 | 4,98 | 52.013 | 17.119.990 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 17.230 | 4.611.909 | 0,37 | 4,98 | 85.874 | 22.985.754 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15.355 | 581.578 | 2,71 | 4,88 | 74.997 | 2.840.543 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 143.403 | 3.424.554 | 4,37 | 4,88 | 700.409 | 16.726.207 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 257.804 | 4.594.679 | 5,94 | 4,88 | 1.259.166 | 22.441.331 | |
| 2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15.472 | 544.363 | 2,93 | 2,75 | 42.548 | 1.496.998 | |
| 2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 250.755 | 3.206.195 | 8,48 | 2,75 | 689.576 | 8.817.036 | |
| 2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 666.385 | 4.306.320 | 18,31 | 2,75 | 1.832.559 | 11.842.380 | |
| 2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 25.107 | 566.223 | 4,64 | 5,04 | 126.414 | 2.850.933 | |
| 2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162.352 | 3.281.151 | 5,21 | 5,04 | 817.442 | 16.520.595 | |
| 2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 157.782 | 4.336.875 | 3,78 | 5,04 | 794.432 | 21.836.166 | |
| 2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
102.400 | ||||||||
| 2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
77.936 | ||||||||
| 2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
13.595 | ||||||||
| 2020-09-24 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32 | 541.116 | 0,01 | 3,80 | 122 | 2.055.537 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7.201 | 1.750.704 | 0,41 | 18,20 | 131.057 | 31.862.463 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.888 | 2.040.124 | 0,49 | 18,20 | 179.960 | 37.129.849 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.991 | 1.743.503 | 0,29 | 18,45 | 92.062 | 32.160.133 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6.960 | 2.030.236 | 0,34 | 18,45 | 128.382 | 37.449.124 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.069 | 1.738.512 | 0,58 | 18,39 | 185.120 | 31.962.717 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 12.259 | 2.023.276 | 0,61 | 18,39 | 225.383 | 37.198.132 | |
| 2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 10.258 | 382.784 | 2,75 | 11,75 | 120.532 | 4.497.712 | |
| 2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 58.745 | 2.200.035 | 2,74 | 11,75 | 690.254 | 25.850.411 | |
| 2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 77.751 | 2.940.553 | 2,72 | 11,75 | 913.574 | 34.551.498 | |
| 2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 12.816 | 372.526 | 3,56 | 11,10 | 142.235 | 4.134.368 | |
| 2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 76.374 | 2.141.290 | 3,70 | 11,10 | 847.614 | 23.764.465 | |
| 2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 100.461 | 2.862.802 | 3,64 | 11,10 | 1.114.936 | 31.771.949 | |
| 2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.830 | 1.728.443 | 0,22 | 18,77 | 71.891 | 32.443.912 | |
| 2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.907 | 2.011.017 | 0,19 | 18,77 | 73.337 | 37.747.996 | |
| 2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 14.339 | 359.710 | 4,15 | 11,17 | 160.167 | 4.017.961 | |
| 2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 82.740 | 2.064.916 | 4,17 | 11,17 | 924.206 | 23.065.112 | |
| 2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 104.827 | 2.762.341 | 3,94 | 11,17 | 1.170.918 | 30.855.349 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7.672 | 1.724.613 | 0,45 | 18,87 | 144.741 | 32.536.721 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.900 | 2.007.110 | 0,50 | 18,87 | 186.774 | 37.866.338 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6.862 | 1.716.941 | 0,40 | 18,48 | 126.814 | 31.730.100 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.143 | 1.997.210 | 0,46 | 18,48 | 168.968 | 36.909.639 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 922 | 1.710.079 | 0,05 | 19,17 | 17.676 | 32.785.464 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.122 | 1.988.067 | 0,06 | 19,17 | 21.511 | 38.115.022 | |
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -180.686 | 0 | -100,00 | ||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.000.955 | 0 | -100,00 | ||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.336.390 | 0 | -100,00 | ||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 67.791 | 181.081 | 59,84 | 20,00 | 1.355.820 | 3.621.620 | |
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 113.290 | 113.290 | |||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 389.709 | 1.017.307 | 62,10 | 20,00 | 7.794.180 | 20.346.140 | |
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 627.598 | 627.598 | |||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 521.193 | 1.359.109 | 62,20 | 20,00 | 10.423.860 | 27.182.180 | |
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 837.916 | 837.916 | |||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | -40.127 | 40.127 | -50,00 | ||||
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2.244 | 1.709.157 | 0,13 | 19,74 | 44.308 | 33.747.305 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.443 | 1.986.945 | 0,17 | 19,74 | 67.982 | 39.232.229 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5.179 | 1.706.913 | 0,30 | 19,31 | 100.003 | 32.959.295 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6.504 | 1.983.502 | 0,33 | 19,31 | 125.588 | 38.300.035 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.607 | 1.701.734 | 0,09 | 19,32 | 31.050 | 32.880.224 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.198 | 1.976.998 | 0,47 | 19,32 | 177.720 | 38.198.765 | |
| 2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 158 | 3.547 | 4,66 | 35,79 | 5.655 | 126.947 | |
| 2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 905 | 20.390 | 4,64 | 35,79 | 32.390 | 729.758 | |
| 2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 1.205 | 27.265 | 4,62 | 35,79 | 43.127 | 975.814 | |
| 2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.772 | 1.967.800 | 0,09 | 19,12 | 33.881 | 37.624.336 | |
| 2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.496 | 1.966.028 | 0,18 | 19,70 | 68.877 | 38.733.897 | |
| 2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 895 | 1.962.532 | 0,05 | 19,27 | 17.246 | 37.816.814 | |
| 2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21.922 | 1.961.637 | 1,13 | 18,69 | 409.810 | 36.670.842 | |
| 2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.050 | 1.939.715 | 0,05 | 17,80 | 18.693 | 34.533.134 | |
| 2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.050 | 1.938.665 | 0,21 | 17,34 | 70.233 | 33.619.359 | |
| 2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 81 | 237.475 | 0,03 | 13,32 | 1.079 | 3.162.312 | |
| 2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 929 | 1.204.981 | 0,08 | 13,32 | 12.371 | 16.046.009 | |
| 2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1.521 | 1.667.420 | 0,09 | 13,32 | 20.254 | 22.204.032 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1.354 | 237.394 | 0,57 | 13,93 | 18.868 | 3.308.014 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 7.854 | 1.204.052 | 0,66 | 13,93 | 109.443 | 16.778.103 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.524 | 1.665.899 | 0,64 | 13,93 | 146.649 | 23.213.803 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 6.769 | 236.040 | 2,95 | 14,39 | 97.403 | 3.396.498 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 39.052 | 1.196.198 | 3,37 | 14,39 | 561.939 | 17.212.691 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 52.443 | 1.655.375 | 3,27 | 14,39 | 754.629 | 23.820.019 | |
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 6.967 | 345.371 | 2,06 | 15,20 | 105.898 | 5.249.639 | |
| 2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 33.321 | 1.982.176 | 1,71 | 15,20 | 506.479 | 30.129.075 | |
| 2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 46.966 | 2.657.514 | 1,80 | 15,20 | 713.883 | 40.394.213 | |
| 2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 94.101 | 338.404 | 38,52 | 14,00 | 1.317.414 | 4.737.656 | |
| 2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 561.966 | 1.948.855 | 40,52 | 14,00 | 7.867.524 | 27.283.970 | |
| 2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 806.443 | 2.610.548 | 44,70 | 14,00 | 11.290.202 | 36.547.672 | |
| 2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -192.250 | 480.432 | -28,58 | 6,00 | -1.153.500 | 2.882.592 | |
| 2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1.064.332 | 2.766.561 | -27,78 | 6,00 | -6.385.992 | 16.599.366 | |
| 2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1.027.016 | 3.712.340 | -21,67 | 6,00 | -6.162.096 | 22.274.040 | |
| 2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4.476 | 541.084 | 0,83 | 4,10 | 18.352 | 2.218.444 | |
| 2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39.810 | 3.118.799 | 1,29 | 4,10 | 163.221 | 12.787.076 | |
| 2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 249.301 | 4.179.093 | 6,34 | 4,10 | 1.022.134 | 17.134.281 | |
| 2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -597 | 0 | -100,00 | ||||
| 2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -656 | 0 | -100,00 | ||||
| 2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 596.813 | 1.700.127 | 54,09 | 13,00 | 7.758.569 | 22.101.651 | |
| 2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 655.959 | 1.934.615 | 51,30 | 13,00 | 8.527.467 | 25.149.995 | |
| 2020-03-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8.264 | 1.278.656 | 0,65 | 17,20 | 142.129 | 21.991.093 | |
| 2020-03-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.439 | 1.270.392 | 0,35 | 14,52 | 64.475 | 18.451.936 | |
| 2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8.113 | 1.265.953 | 0,64 | 15,73 | 127.648 | 19.918.125 | |
| 2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.164 | 1.257.840 | 0,81 | 15,73 | 159.916 | 19.790.351 | |
| 2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 100.000 | 1.247.676 | 8,71 | 18,34 | 1.834.090 | 22.883.501 | |
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 12 | 12 | |||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 87 | 191 | 83,65 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 841 | 1.250 | 205,62 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 981 | 1.594 | 160,03 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 104 | 104 | |||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -104 | 0 | -100,00 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 409 | 409 | |||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -409 | 0 | -100,00 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 613 | 613 | |||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -613 | 0 | -100,00 | ||||
| 2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -74.893 | 424.419 | -15,00 | 15,79 | -1.182.321 | 6.700.218 | |
| 2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -510.793 | 2.350.829 | -17,85 | 15,79 | -8.063.787 | 37.112.067 | |
| 2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -486.344 | 3.131.432 | -13,44 | 15,79 | -7.677.815 | 49.435.291 | |
| 2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 19.727 | 244.303 | 8,78 | 16,15 | 318.591 | 3.945.493 | |
| 2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 112.561 | 1.386.889 | 8,83 | 16,15 | 1.817.860 | 22.398.257 | |
| 2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 146.442 | 1.804.105 | 8,83 | 16,15 | 2.365.038 | 29.136.296 | |
| 2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 5.406 | 224.576 | 2,47 | 14,98 | 80.973 | 3.363.789 | |
| 2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 25.108 | 1.274.328 | 2,01 | 14,98 | 376.078 | 19.087.395 | |
| 2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53.448 | 1.657.663 | 3,33 | 14,98 | 800.566 | 24.829.139 | |
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32.606 | 536.608 | 6,47 | 4,05 | 132.054 | 2.173.262 | |
| 2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 201.096 | 3.078.989 | 6,99 | 4,05 | 814.439 | 12.469.905 | |
| 2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 281.318 | 3.929.792 | 7,71 | 4,05 | 1.139.338 | 15.915.658 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 165.961 | 1.103.314 | 17,71 | 22,00 | 3.651.142 | 24.272.908 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 207.234 | 1.147.676 | 22,04 | 22,00 | 4.559.148 | 25.248.872 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -35.888 | 0 | -100,00 | ||||
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -190.899 | 0 | -100,00 | ||||
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -245.481 | 0 | -100,00 | ||||
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 35.888 | 159.537 | 29,02 | 22,00 | 789.536 | 3.509.814 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 190.899 | 937.353 | 25,57 | 22,00 | 4.199.778 | 20.621.766 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 245.481 | 940.442 | 35,32 | 22,00 | 5.400.582 | 20.689.724 | |
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 8.506 | 499.312 | 1,73 | 9,52 | 80.935 | 4.750.954 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 49.804 | 2.861.622 | 1,77 | 9,52 | 473.885 | 27.228.333 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 60.103 | 3.617.776 | 1,69 | 9,52 | 571.880 | 34.423.139 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15.030 | 490.806 | 3,16 | 9,40 | 141.282 | 4.613.576 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 95.100 | 2.811.818 | 3,50 | 9,40 | 893.940 | 26.431.089 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 113.529 | 3.557.673 | 3,30 | 9,40 | 1.067.173 | 33.442.126 | |
| 2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.397 | 504.002 | 0,48 | 4,02 | 9.630 | 2.024.828 | |
| 2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18.729 | 2.877.893 | 0,66 | 4,02 | 75.244 | 11.561.935 | |
| 2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 113.874 | 3.648.474 | 3,22 | 4,02 | 457.489 | 14.657.744 | |
| 2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81.857 | 501.605 | 19,50 | 3,40 | 278.322 | 1.705.507 | |
| 2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 462.056 | 2.859.164 | 19,28 | 3,40 | 1.571.037 | 9.721.444 | |
| 2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 576.097 | 3.534.600 | 19,47 | 3,40 | 1.958.787 | 12.017.993 | |
| 2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14.151 | 672.682 | 2,15 | 3,91 | 55.353 | 2.631.263 | |
| 2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 79.285 | 3.830.893 | 2,11 | 3,91 | 310.131 | 14.984.921 | |
| 2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 98.518 | 4.739.356 | 2,12 | 3,91 | 385.363 | 18.538.465 | |
| 2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11.105 | 658.531 | 1,72 | 3,37 | 37.424 | 2.219.249 | |
| 2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45.888 | 3.751.608 | 1,24 | 3,37 | 154.643 | 12.642.919 | |
| 2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 71.495 | 4.640.838 | 1,56 | 3,37 | 240.938 | 15.639.624 | |
| 2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 70.921 | 419.748 | 20,33 | 4,00 | 283.684 | 1.678.992 | |
| 2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 400.470 | 2.397.108 | 20,06 | 4,00 | 1.601.880 | 9.588.432 | |
| 2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 496.721 | 2.958.503 | 20,18 | 4,00 | 1.986.884 | 11.834.012 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57.868 | 647.426 | 9,82 | 2,70 | 156.244 | 1.748.050 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 331.048 | 3.705.720 | 9,81 | 2,70 | 893.830 | 10.005.444 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 408.592 | 4.569.343 | 9,82 | 2,70 | 1.103.198 | 12.337.226 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 116.552 | 589.558 | 24,64 | 2,60 | 303.035 | 1.532.851 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 610.052 | 3.374.672 | 22,07 | 2,60 | 1.586.135 | 8.774.147 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 872.373 | 4.160.751 | 26,53 | 2,60 | 2.268.170 | 10.817.953 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 504 | 348.827 | 0,14 | 3,85 | 1.940 | 1.342.844 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.913 | 1.996.638 | 0,15 | 3,85 | 11.214 | 7.686.258 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3.416 | 2.461.782 | 0,14 | 3,85 | 13.150 | 9.476.876 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.456 | 348.323 | 0,42 | 3,89 | 5.667 | 1.355.708 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8.236 | 1.993.725 | 0,41 | 3,89 | 32.055 | 7.759.777 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10.389 | 2.458.366 | 0,42 | 3,89 | 40.435 | 9.568.206 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 240 | 346.867 | 0,07 | 3,90 | 935 | 1.351.706 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.133 | 1.985.489 | 0,06 | 3,90 | 4.415 | 7.737.252 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.027 | 2.447.977 | 0,04 | 3,90 | 4.002 | 9.539.522 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.155 | 346.627 | 0,63 | 3,75 | 8.075 | 1.298.915 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 12.899 | 1.984.356 | 0,65 | 3,75 | 48.336 | 7.435.977 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15.728 | 2.446.950 | 0,65 | 3,75 | 58.938 | 9.169.456 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.629 | 344.472 | 0,48 | 3,74 | 6.100 | 1.289.944 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 57.723 | 1.971.457 | 3,02 | 3,74 | 216.155 | 7.382.515 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 76.036 | 2.431.222 | 3,23 | 3,74 | 284.732 | 9.104.197 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3.200 | 2.355.186 | 0,14 | 3,75 | 11.986 | 8.821.349 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4.689 | 342.843 | 1,39 | 3,68 | 17.270 | 1.262.691 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24.716 | 1.913.734 | 1,31 | 3,68 | 91.029 | 7.048.282 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 31.007 | 2.351.986 | 1,34 | 3,68 | 114.199 | 8.662.364 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24.425 | 338.154 | 7,79 | 3,75 | 91.594 | 1.268.078 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 14.242 | 313.729 | 4,76 | 3,75 | 53.382 | 1.175.919 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 138.609 | 1.889.018 | 7,92 | 3,75 | 519.784 | 7.083.818 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 80.821 | 1.750.409 | 4,84 | 3,75 | 302.933 | 6.560.883 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 168.640 | 2.320.979 | 7,84 | 3,75 | 632.400 | 8.703.671 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 98.333 | 2.152.339 | 4,79 | 3,75 | 368.572 | 8.067.397 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 991 | 299.487 | 0,33 | 3,74 | 3.704 | 1.119.333 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7.314 | 1.669.588 | 0,44 | 3,74 | 27.336 | 6.240.085 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7.695 | 2.054.006 | 0,38 | 3,74 | 28.760 | 7.676.847 | |
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1.128 | 314.139 | -0,36 | 4,50 | -5.075 | 1.413.437 | |
| 2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -25.720 | 2.233.074 | -1,14 | 4,50 | -115.725 | 10.047.493 | |
| 2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -23.152 | 2.385.055 | -0,96 | 4,50 | -104.170 | 10.731.316 | |
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 124.956 | 528.891 | 30,93 | 3,18 | 397.610 | 1.682.931 | |
| 2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 689.834 | 2.955.440 | 30,45 | 3,18 | 2.195.052 | 9.404.210 | |
| 2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 853.956 | 3.639.935 | 30,65 | 3,18 | 2.717.288 | 11.582.273 | |
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -29.450 | 169.589 | -14,80 | 10,70 | -315.230 | 1.815.264 | |
| 2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -158.583 | 952.859 | -14,27 | 10,70 | -1.697.457 | 10.199.307 | |
| 2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -198.256 | 1.178.904 | -14,40 | 10,70 | -2.122.112 | 12.618.871 | |
| 2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13.816 | 746.454 | 1,89 | 14,74 | 203.664 | 11.003.628 | |
| 2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.797 | 732.638 | 0,52 | 14,36 | 54.526 | 10.520.975 | |
| 2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.300 | 728.841 | 1,43 | 14,57 | 150.037 | 10.616.808 | |
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 284 | 284 | |||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2.143 | 2.143 | |||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2.573 | 2.573 | |||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -284.000 | 141.346 | -66,77 | ||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2.143.000 | 772.324 | -73,51 | ||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2.573.000 | 978.200 | -72,45 | ||||
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 372 | 597 | 165,47 | 13.000,00 | 4.836.000 | 7.758.569 | |
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 311 | 656 | 89,96 | 13.000,00 | 4.038.398 | 8.527.467 | |
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25.000 | 718.541 | 3,60 | 14,19 | 354.792 | 10.197.318 | |
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 225 | 225 | 13.000,00 | 2.922.569 | 2.922.569 | ||
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -225 | 0 | -100,00 | ||||
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 345 | 345 | 13.000,00 | 4.489.069 | 4.489.069 | ||
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -345 | 0 | -100,00 | ||||
| 2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 120.539 | 6.631.136 | 1,85 | 1,20 | 144.587 | 7.954.048 | |
| 2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 54.461 | 8.485.575 | 0,65 | 1,20 | 65.326 | 10.178.447 | |
| 2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 24.253 | 693.541 | 3,62 | 14,41 | 349.525 | 9.995.035 | |
| 2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2.810 | 669.288 | 0,42 | 14,75 | 41.448 | 9.871.998 | |
| 2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.400 | 666.478 | 1,43 | 14,50 | 136.270 | 9.661.798 | |
| 2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 18.081 | 657.078 | 2,83 | 14,54 | 262.972 | 9.556.608 | |
| 2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 32.015 | 638.997 | 5,27 | 14,77 | 472.778 | 9.436.324 | |
| 2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.927 | 606.982 | 1,83 | 14,80 | 161.698 | 8.982.120 | |
| 2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.171 | 596.055 | 0,70 | 14,99 | 62.515 | 8.933.672 | |
| 2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 806 | 591.884 | 0,14 | 14,90 | 12.009 | 8.819.072 | |
| 2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.823 | 591.078 | 0,82 | 14,85 | 71.615 | 8.776.681 | |
| 2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -89.948 | 370.391 | -19,54 | 1,83 | -164.929 | 679.149 | |
| 2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -382.017 | 1.942.764 | -16,43 | 1,83 | -700.466 | 3.562.252 | |
| 2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -430.035 | 2.502.758 | -14,66 | 1,83 | -788.512 | 4.589.057 | |
| 2018-11-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 100.000 | 6.510.597 | 1,56 | 1,30 | 130.000 | 8.463.776 | |
| 2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.016 | 586.255 | 1,74 | 14,93 | 149.543 | 8.753.022 | |
| 2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8.288 | 576.239 | 1,46 | 15,11 | 125.262 | 8.709.046 | |
| 2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 11.396 | 567.951 | 2,05 | 15,24 | 173.680 | 8.655.800 | |
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25.000 | 556.555 | 4,70 | 15,00 | 374.892 | 8.345.932 | |
| 2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 37.482 | 531.555 | 7,59 | 13,68 | 512.701 | 7.270.928 | |
| 2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.771 | 494.073 | 2,02 | 13,93 | 136.064 | 6.880.115 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 581 | 1.254.993 | 0,05 | 1,35 | 784 | 1.694.241 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4.119 | 8.431.114 | 0,05 | 1,35 | 5.561 | 11.382.004 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 5.573 | 1.254.412 | 0,45 | 1,35 | 7.524 | 1.693.456 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 38.001 | 6.410.597 | 0,60 | 1,35 | 51.301 | 8.654.306 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 50.044 | 8.426.995 | 0,60 | 1,35 | 67.559 | 11.376.443 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81.648 | 1.248.839 | 7,00 | 1,37 | 111.841 | 1.710.660 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 556.709 | 6.372.596 | 9,57 | 1,37 | 762.580 | 8.729.182 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 733.151 | 8.376.951 | 9,59 | 1,37 | 1.004.270 | 11.474.747 | |
| 2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.849 | 484.302 | 2,29 | 13,82 | 149.986 | 6.695.427 | |
| 2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21.141 | 473.453 | 4,67 | 13,31 | 281.361 | 6.301.091 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39.074 | 5.815.887 | 0,68 | 1,35 | 52.750 | 7.851.447 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52.400 | 7.643.800 | 0,69 | 1,35 | 70.740 | 10.319.130 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 92.960 | 5.776.813 | 1,64 | 1,34 | 124.566 | 7.740.929 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 117.290 | 7.591.400 | 1,57 | 1,34 | 157.169 | 10.172.476 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 562.754 | 5.683.853 | 10,99 | 1,35 | 759.718 | 7.673.202 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 41.454 | 7.474.110 | 0,56 | 1,35 | 55.963 | 10.090.048 | |
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 36.825 | 1.167.191 | 3,26 | 1,65 | 60.761 | 1.925.865 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 158.151 | 5.121.099 | 3,19 | 1,65 | 260.949 | 8.449.813 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 230.555 | 7.432.656 | 3,20 | 1,65 | 380.416 | 12.263.882 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 179.893 | 1.130.366 | 18,93 | 1,65 | 296.823 | 1.865.104 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.419.907 | 4.962.948 | 40,08 | 1,65 | 2.342.847 | 8.188.864 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.916.760 | 7.202.101 | 36,27 | 1,65 | 3.162.654 | 11.883.467 | |
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 188.746 | 188.746 | |||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 705.863 | 705.863 | |||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 1.105.391 | 1.105.391 | |||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -188.746 | 85.038 | -68,94 | ||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -705.863 | 318.021 | -68,94 | ||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -1.105.391 | 498.025 | -68,94 | ||||
| 2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -175.813 | 771.305 | -18,56 | 5,00 | -879.083 | 3.856.602 | |
| 2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -312.266 | 3.186.044 | -8,93 | 5,00 | -1.561.361 | 15.930.539 | |
| 2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -547.860 | 4.682.669 | -10,47 | 5,00 | -2.739.355 | 23.413.813 | |
| 2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -217.256 | 947.118 | -18,66 | 3,10 | -673.494 | 2.936.066 | |
| 2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -808.449 | 3.498.310 | -18,77 | 3,10 | -2.506.192 | 10.844.761 | |
| 2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1.204.668 | 5.230.529 | -18,72 | 3,10 | -3.734.471 | 16.214.640 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 97.453 | 950.473 | 11,42 | 2,00 | 194.906 | 1.900.946 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 365.682 | 3.543.041 | 11,51 | 2,00 | 731.364 | 7.086.082 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 546.865 | 5.285.341 | 11,54 | 2,00 | 1.093.730 | 10.570.682 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 62.437 | 853.020 | 7,90 | 1,90 | 118.630 | 1.620.738 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 208.872 | 3.177.359 | 7,04 | 1,90 | 396.857 | 6.036.982 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 228.691 | 4.738.476 | 5,07 | 1,90 | 434.513 | 9.003.104 | |
| 2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -214.336 | 1.164.374 | -15,55 | 2,90 | -621.574 | 3.376.685 | |
| 2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -817.611 | 4.306.759 | -15,96 | 2,90 | -2.371.072 | 12.489.601 | |
| 2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1.269.634 | 6.435.197 | -16,48 | 2,90 | -3.681.939 | 18.662.071 | |
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 238.000 | 238.000 | |||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 861.000 | 861.000 | |||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 1.338.000 | 1.338.000 | |||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -238.000 | 59.464 | -80,01 | ||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -861.000 | 216.694 | -79,89 | ||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -1.338.000 | 336.468 | -79,91 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 2.280 | 2.280 | |||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 1.024 | 1.024 | |||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 3.640 | 3.640 | |||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 5.631 | 5.631 | |||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -49 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -48 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -197 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -281 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 699.225 | 1.295.582 | 117,25 | 3,00 | 2.097.675 | 3.886.746 | |
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 483.708 | 483.708 | 3,00 | 1.451.124 | 1.451.124 | ||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 2.109.280 | 2.109.280 | 3,00 | 6.327.840 | 6.327.840 | ||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 3.041.120 | 3.041.120 | 3,00 | 9.123.360 | 9.123.360 | ||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -1.487.294 | 596.357 | -71,38 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -651.074 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -2.295.083 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -3.566.549 | 0 | -100,00 | ||||
| 2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -169.292 | 122.496 | -58,02 | 26,65 | -4.511.632 | 3.264.518 | |
| 2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -445.615 | 632.642 | -41,33 | 26,65 | -11.875.640 | 16.859.909 | |
| 2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -667.949 | 951.300 | -41,25 | 26,65 | -17.800.841 | 25.352.145 | |
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 34.632 | 291.788 | 13,47 | 15,84 | 548.484 | 4.621.192 | |
| 2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 135.206 | 1.078.257 | 14,34 | 15,84 | 2.141.325 | 17.076.895 | |
| 2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162.078 | 1.619.249 | 11,12 | 15,84 | 2.566.910 | 25.644.856 | |
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 63.042 | 790.583 | 8,67 | 1,28 | 80.946 | 1.015.109 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 235.326 | 2.968.487 | 8,61 | 1,28 | 302.159 | 3.811.537 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 355.081 | 4.509.785 | 8,55 | 1,28 | 455.924 | 5.790.564 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 28.918 | 727.541 | 4,14 | 1,24 | 35.714 | 898.513 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 394.078 | 2.733.161 | 16,85 | 1,24 | 486.686 | 3.375.454 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 523.601 | 4.154.704 | 14,42 | 1,24 | 646.647 | 5.131.059 | |
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 7.429 | 1.077.694 | 0,69 | 2,41 | 17.920 | 2.599.613 | |
| 2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 11.429 | 1.674.468 | 0,69 | 2,41 | 27.569 | 4.039.152 | |
| 2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 13.337 | 1.070.265 | 1,26 | 2,70 | 36.058 | 2.893.568 | |
| 2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 28.007 | 1.663.039 | 1,71 | 2,70 | 75.720 | 4.496.192 | |
| 2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -105.713 | 890.487 | -10,61 | 0,06 | -6.343 | 53.429 | |
| 2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -242.236 | 1.377.652 | -14,95 | 0,06 | -14.534 | 82.659 | |
| 2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -3.993.637 | 0 | -100,00 | 0,06 | -239.618 | ||
| 2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8.496 | 297.464 | 2,94 | 3,04 | 25.795 | 903.130 | |
| 2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30.170 | 1.056.928 | 2,94 | 3,04 | 91.599 | 3.208.939 | |
| 2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46.795 | 1.635.032 | 2,95 | 3,04 | 142.074 | 4.964.121 | |
| 2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8.496 | 297.464 | 2,94 | 4,00 | 33.984 | 1.189.856 | |
| 2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30.170 | 1.056.928 | 2,94 | 4,00 | 120.680 | 4.227.712 | |
| 2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46.795 | 1.635.032 | 2,95 | 4,00 | 187.180 | 6.540.128 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 854 | 288.968 | 0,30 | 4,00 | 3.416 | 1.155.872 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 2.884 | 1.026.758 | 0,28 | 4,00 | 11.536 | 4.107.032 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4.525 | 1.588.237 | 0,29 | 4,00 | 18.100 | 6.352.948 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.362 | 288.114 | 0,47 | 4,00 | 5.448 | 1.152.456 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4.406 | 1.023.874 | 0,43 | 4,00 | 17.624 | 4.095.496 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6.380 | 1.583.712 | 0,40 | 4,00 | 25.520 | 6.334.848 | |
| 2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.715 | 201.811 | 0,86 | 2,25 | 3.859 | 454.075 | |
| 2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.359 | 717.089 | 0,89 | 2,25 | 14.308 | 1.613.450 | |
| 2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 9.732 | 1.109.258 | 0,89 | 2,25 | 21.897 | 2.495.830 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 357 | 286.752 | 0,12 | 3,85 | 1.374 | 1.103.995 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.271 | 1.019.468 | 0,12 | 3,85 | 4.893 | 3.924.952 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.967 | 1.577.332 | 0,12 | 3,85 | 7.573 | 6.072.728 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.064 | 286.395 | 0,37 | 3,85 | 4.096 | 1.102.621 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3.873 | 1.018.197 | 0,38 | 3,85 | 14.911 | 3.920.058 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6.097 | 1.575.365 | 0,39 | 3,85 | 23.473 | 6.065.155 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.160 | 285.331 | 0,41 | 3,84 | 4.451 | 1.094.815 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3.845 | 1.014.324 | 0,38 | 3,84 | 14.753 | 3.891.961 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6.774 | 1.569.268 | 0,43 | 3,84 | 25.992 | 6.021.281 | |
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -536 | 49 | -91,62 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -513 | 48 | -91,44 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -2.115 | 197 | -91,48 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -3.011 | 281 | -91,46 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 585 | 585 | |||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 561 | 561 | |||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 2.312 | 2.312 | |||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 3.292 | 3.292 | |||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 357.333 | 2.083.651 | 20,70 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 342.000 | 651.074 | 110,65 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 1.410.000 | 2.295.083 | 159,31 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 2.007.333 | 3.566.549 | 128,74 | ||||
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 20.594 | 284.171 | 7,81 | 3,85 | 79.312 | 1.094.399 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 73.749 | 1.010.479 | 7,87 | 3,85 | 284.022 | 3.891.557 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 113.446 | 1.562.494 | 7,83 | 3,85 | 436.903 | 6.017.477 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 913 | 263.577 | 0,35 | 3,75 | 3.424 | 988.414 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 53.260 | 936.730 | 6,03 | 3,75 | 199.725 | 3.512.738 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 96.736 | 1.449.048 | 7,15 | 3,75 | 362.760 | 5.433.930 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.673 | 200.096 | 1,87 | 2,28 | 8.379 | 456.479 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 13.046 | 710.730 | 1,87 | 2,28 | 29.762 | 1.621.388 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 20.181 | 1.099.526 | 1,87 | 2,28 | 46.039 | 2.508.349 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.920 | 196.423 | 2,04 | 2,29 | 8.979 | 449.927 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 12.624 | 697.684 | 1,84 | 2,29 | 28.917 | 1.598.115 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 19.206 | 1.079.345 | 1,81 | 2,29 | 43.993 | 2.472.348 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2.727 | 192.503 | 1,44 | 2,25 | 6.128 | 432.554 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10.023 | 685.060 | 1,48 | 2,25 | 22.522 | 1.539.330 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 15.350 | 1.060.139 | 1,47 | 2,25 | 34.491 | 2.382.132 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.805 | 189.776 | 0,96 | 2,30 | 4.144 | 435.669 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.903 | 675.037 | 1,03 | 2,30 | 15.847 | 1.549.682 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10.192 | 1.044.789 | 0,99 | 2,30 | 23.398 | 2.398.522 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.124 | 187.971 | 0,60 | 2,30 | 2.585 | 432.333 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 4.223 | 668.134 | 0,64 | 2,30 | 9.713 | 1.536.708 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.253 | 1.034.597 | 0,61 | 2,30 | 14.382 | 2.379.573 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2.909 | 186.847 | 1,58 | 2,30 | 6.690 | 429.711 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10.541 | 663.911 | 1,61 | 2,30 | 24.242 | 1.526.863 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 16.436 | 1.028.344 | 1,62 | 2,30 | 37.800 | 2.364.986 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 5.510 | 183.938 | 3,09 | 2,30 | 12.666 | 422.818 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.897 | 653.370 | 1,07 | 2,30 | 15.854 | 1.501.902 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 24.965 | 1.011.908 | 2,53 | 2,30 | 57.387 | 2.326.073 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 675 | 178.428 | 0,38 | 2,34 | 1.581 | 418.039 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2.565 | 646.473 | 0,40 | 2,34 | 6.010 | 1.514.622 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.794 | 986.943 | 0,39 | 2,34 | 8.889 | 2.312.309 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.217 | 177.753 | 3,62 | 2,35 | 14.583 | 416.955 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 22.092 | 643.908 | 3,55 | 2,35 | 51.821 | 1.510.415 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 33.691 | 983.149 | 3,55 | 2,35 | 79.029 | 2.306.173 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.929 | 171.536 | 2,34 | 2,29 | 8.989 | 392.457 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 14.274 | 621.816 | 2,35 | 2,29 | 32.657 | 1.422.653 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 21.797 | 949.458 | 2,35 | 2,29 | 49.869 | 2.172.265 | |
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3.234 | 2.339.083 | 0,14 | 1,34 | 4.333 | 3.133.669 | |
| 2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.145 | 3.631.103 | 0,03 | 1,34 | 1.534 | 4.864.589 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.205 | 2.335.849 | 0,05 | 1,34 | 1.614 | 3.129.103 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.348 | 3.629.958 | 0,06 | 1,34 | 3.145 | 4.862.692 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 77.076 | 698.623 | 12,40 | 1,34 | 102.943 | 933.081 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 260.046 | 2.334.644 | 12,53 | 1,34 | 347.317 | 3.118.151 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 401.726 | 3.627.610 | 12,45 | 1,34 | 536.545 | 4.845.036 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.244 | 621.547 | 0,36 | 1,35 | 3.040 | 842.134 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8.111 | 2.074.598 | 0,39 | 1,35 | 10.990 | 2.810.873 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 11.646 | 3.225.884 | 0,36 | 1,35 | 15.779 | 4.370.750 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 21.021 | 619.303 | 3,51 | 1,36 | 28.555 | 841.261 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 69.041 | 2.066.487 | 3,46 | 1,36 | 93.785 | 2.807.116 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 108.202 | 3.214.238 | 3,48 | 1,36 | 146.982 | 4.366.221 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 47.812 | 598.282 | 8,69 | 1,28 | 61.199 | 765.801 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 150.451 | 1.997.446 | 8,15 | 1,28 | 192.577 | 2.556.731 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 236.393 | 3.106.036 | 8,24 | 1,28 | 302.583 | 3.975.726 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.916 | 550.470 | 0,53 | 1,19 | 3.470 | 655.114 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18.586 | 1.846.995 | 1,02 | 1,19 | 22.119 | 2.198.109 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 30.998 | 2.869.643 | 1,09 | 1,19 | 36.891 | 3.415.162 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15.161 | 547.554 | 2,85 | 1,18 | 17.958 | 648.578 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52.457 | 1.828.409 | 2,95 | 1,18 | 62.135 | 2.165.750 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81.276 | 2.838.645 | 2,95 | 1,18 | 96.271 | 3.362.375 | |
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 6.197 | 6.197 | 800,00 | 4.957.600 | 4.957.600 | ||
| 2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 1.029 | 1.029 | 800,00 | 823.200 | 823.200 | ||
| 2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 4.519 | 4.519 | 800,00 | 3.615.200 | 3.615.200 | ||
| 2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 5.505 | 5.505 | 800,00 | 4.404.000 | 4.404.000 | ||
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 58.613 | 17.263.200 | 0,34 | 1,22 | 71.338 | 21.011.041 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 32.571 | 3.090.744 | 1,07 | 1,22 | 39.642 | 3.761.745 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 90.049 | 8.850.836 | 1,03 | 1,22 | 109.599 | 10.772.352 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 186.314 | 15.592.160 | 1,21 | 1,22 | 226.763 | 18.977.218 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 8.091 | 17.204.587 | 0,05 | 1,22 | 9.848 | 20.939.703 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 29.655 | 3.058.173 | 0,98 | 1,22 | 36.093 | 3.722.102 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 87.747 | 8.760.787 | 1,01 | 1,22 | 106.797 | 10.662.754 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 508.287 | 15.405.846 | 3,41 | 1,22 | 618.636 | 18.750.455 | |
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
J - Other | -2.384.577 | 0 | -100,00 | ||||
| 2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -287.000 | 2.384.577 | -10,74 | 7,00 | -2.009.057 | 16.692.516 | |
| 2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -73.000 | 2.671.577 | -2,66 | 6,98 | -509.343 | 18.640.394 | |
| 2015-11-02 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -50.000 | 2.744.577 | -1,79 | 6,97 | -348.515 | 19.130.525 | |
| 2015-06-11 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -31.000 | 2.794.577 | -1,10 | 9,01 | -279.229 | 25.171.873 | |
| 2015-06-11 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -924.700 | 2.825.577 | -24,66 | 9,00 | -8.322.392 | 25.430.476 | |
| 2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Preferred Stock, $0.0001 per share |
J - Other | 1.400 | 1.400 | |||||
| 2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Preferred Stock, $0.0001 per share |
J - Other | 2.600 | 2.600 | |||||
| 2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -1.400.000 | 1.898.293 | -42,45 | ||||
| 2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -2.600.000 | 3.762.683 | -40,86 | ||||
| 2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 55.197 | 3.298.293 | 1,70 | 1,73 | 95.662 | 5.716.272 | |
| 2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 98.298 | 6.362.683 | 1,57 | 1,73 | 170.360 | 11.027.166 | |
| 2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 79.434 | 3.243.096 | 2,51 | 1,88 | 149.249 | 6.093.453 | |
| 2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 145.515 | 6.264.385 | 2,38 | 1,88 | 273.408 | 11.770.153 | |
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15.401.402 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12.446.194 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15.401.402 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12.446.194 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15.401.402 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12.446.194 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15.401.402 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12.446.194 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15.401.402 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12.446.194 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15.401.402 | ||||||||
| 2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12.446.194 | ||||||||
| 2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Warrants |
J - Other | -242.814 | 1.223.484 | -16,56 | 1,59 | -386.074 | 1.945.340 | |
| 2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Warrants |
J - Other | -407.136 | 2.288.698 | -15,10 | 1,59 | -647.346 | 3.639.030 | |
| 2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -258.230 | 2.412.290 | -9,67 | 3,24 | -836.665 | 7.815.820 | |
| 2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -296.008 | 4.512.523 | -6,16 | 3,24 | -959.066 | 14.620.575 | |
| 2014-07-10 |
|
4 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
J - Other | -494.092 | 7.058.997 | -6,54 | 4,56 | -2.253.060 | 32.189.026 | |
| 2014-07-03 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
J - Other | -616.563 | 3.993.637 | -13,37 | 0,30 | -184.969 | 1.198.091 | |
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16.369.219 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14.974.663 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20.518.746 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16.369.219 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14.974.663 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20.518.746 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16.369.219 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14.974.663 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20.518.746 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16.369.219 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14.974.663 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20.518.746 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16.369.219 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14.974.663 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20.518.746 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16.369.219 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14.974.663 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20.518.746 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16.369.219 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14.974.663 | ||||||||
| 2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20.518.746 | ||||||||
| 2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -10.203 | 130.175 | -7,27 | 69,95 | -713.734 | 9.106.171 | |
| 2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18.019 | 230.125 | -7,26 | 69,95 | -1.260.489 | 16.098.003 | |
| 2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18.306 | 140.378 | -11,54 | 70,17 | -1.284.483 | 9.849.945 | |
| 2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -31.698 | 248.144 | -11,33 | 70,17 | -2.224.163 | 17.411.594 | |
| 2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Preferred Stock, $0.001 per share |
J - Other | 2.632 | 2.632 | |||||
| 2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Preferred Stock, $0.001 per share |
J - Other | 4.577 | 4.577 | |||||
| 2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock, $0.001 par value |
J - Other | -526.436 | 1.121.221 | -31,95 | ||||
| 2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock, $0.001 par value |
J - Other | -915.345 | 1.979.670 | -31,62 | ||||
| 2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -200.827 | 2.494.521 | -7,45 | 1,09 | -218.901 | 2.719.028 | |
| 2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -33.610 | 438.127 | -7,12 | 1,09 | -36.635 | 477.558 | |
| 2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -59.388 | 772.480 | -7,14 | 1,09 | -64.733 | 842.003 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -33.236 | 2.695.348 | -1,22 | 1,11 | -36.869 | 2.989.950 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -4.416 | 471.737 | -0,93 | 1,11 | -4.899 | 523.298 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -7.745 | 831.868 | -0,92 | 1,11 | -8.592 | 922.791 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -151.535 | 2.728.584 | -5,26 | 1,12 | -169.659 | 3.054.923 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -25.060 | 476.153 | -5,00 | 1,12 | -28.057 | 533.101 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -44.147 | 839.613 | -5,00 | 1,12 | -49.427 | 940.031 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -191.804 | 2.880.119 | -6,24 | 1,16 | -222.838 | 3.346.122 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -29.710 | 501.213 | -5,60 | 1,16 | -34.517 | 582.309 | |
| 2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -52.528 | 883.760 | -5,61 | 1,16 | -61.027 | 1.026.752 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -5.359 | 79.390 | -6,32 | 73,05 | -391.464 | 5.799.273 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -112.369 | 1.685.344 | -6,25 | 73,05 | -8.208.319 | 123.110.840 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -10.557 | 158.684 | -6,24 | 73,05 | -771.167 | 11.591.533 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18.615 | 279.842 | -6,24 | 73,05 | -1.359.787 | 20.441.870 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -2.771 | 84.749 | -3,17 | 73,03 | -202.375 | 6.189.499 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -57.370 | 1.797.713 | -3,09 | 73,03 | -4.189.920 | 131.292.913 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -5.395 | 169.241 | -3,09 | 73,03 | -394.015 | 12.360.229 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -9.464 | 298.457 | -3,07 | 73,03 | -691.187 | 21.797.300 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -14.003 | 87.520 | -13,79 | 74,66 | -1.045.409 | 6.533.902 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -153.751 | 1.855.083 | -7,65 | 74,66 | -11.478.450 | 138.493.262 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -16.331 | 174.636 | -8,55 | 74,66 | -1.219.209 | 13.037.643 | |
| 2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -16.915 | 307.921 | -5,21 | 74,66 | -1.262.808 | 22.988.181 | |
| 2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -19.077 | 3.071.923 | -0,62 | 1,11 | -21.216 | 3.416.286 | |
| 2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -10.470 | 530.923 | -1,93 | 1,11 | -11.644 | 590.439 | |
| 2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -14.059 | 936.288 | -1,48 | 1,11 | -15.635 | 1.041.246 | |
| 2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -110.885 | 541.393 | -17,00 | 1,18 | -130.623 | 637.761 | |
| 2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -122.443 | 950.347 | -11,41 | 1,18 | -144.238 | 1.119.509 | |
| 2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -15.622 | 652.278 | -2,34 | 1,16 | -18.139 | 757.360 | |
| 2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -13.410 | 1.072.790 | -1,23 | 1,16 | -15.570 | 1.245.616 | |
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5.080.487 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4.222.129 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5.080.487 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4.222.129 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5.080.487 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4.222.129 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5.080.487 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4.222.129 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5.080.487 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4.222.129 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5.080.487 | ||||||||
| 2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4.222.129 | ||||||||
| 2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 41.451 | 1.251.914 | 3,42 | 5,03 | 208.358 | 6.292.871 | |
| 2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 82.849 | 2.162.381 | 3,98 | 5,03 | 416.449 | 10.869.424 | |
| 2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 16.175 | 1.210.463 | 1,35 | 4,98 | 80.590 | 6.031.011 | |
| 2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 49.325 | 2.079.532 | 2,43 | 4,98 | 245.757 | 10.361.060 | |
| 2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -154.578 | 2.008.834 | -7,15 | 57,07 | -8.822.493 | 114.653.598 | |
| 2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -27.058 | 101.523 | -21,04 | 57,07 | -1.544.327 | 5.794.395 | |
| 2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -50.934 | 190.967 | -21,06 | 57,07 | -2.907.043 | 10.899.384 | |
| 2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -86.435 | 324.836 | -21,02 | 57,07 | -4.933.252 | 18.539.917 | |
| 2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -34.917 | 128.581 | -21,36 | 57,57 | -2.010.172 | 7.402.408 | |
| 2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -54.444 | 241.901 | -18,37 | 57,57 | -3.134.341 | 13.926.241 | |
| 2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -119.139 | 411.271 | -22,46 | 57,57 | -6.858.832 | 23.676.871 | |
| 2013-11-20 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -153.056 | 646.559 | -19,14 | 2,64 | -404.343 | 1.708.080 | |
| 2013-11-20 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -331.566 | 1.123.848 | -22,78 | 2,64 | -875.931 | 2.968.982 | |
| 2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 8.371 | 1.194.288 | 0,71 | 4,69 | 39.235 | 5.597.628 | |
| 2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 11.985 | 2.030.207 | 0,59 | 4,69 | 56.174 | 9.515.580 | |
| 2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 74.684 | 1.185.917 | 6,72 | 4,97 | 370.978 | 5.890.806 | |
| 2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 35.526 | 2.018.222 | 1,79 | 4,97 | 176.468 | 10.025.114 | |
| 2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 5.500 | 1.111.233 | 0,50 | 4,90 | 26.944 | 5.443.819 | |
| 2013-11-05 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 79.360 | 2.670.520 | 3,06 | 1,78 | 141.261 | 4.753.526 | |
| 2013-11-05 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 49.640 | 4.808.531 | 1,04 | 1,78 | 88.359 | 8.559.185 | |
| 2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 25.154 | 1.105.733 | 2,33 | 4,92 | 123.775 | 5.440.980 | |
| 2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 45.406 | 1.982.696 | 2,34 | 4,92 | 223.429 | 9.756.252 | |
| 2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 44.584 | 1.080.579 | 4,30 | 4,97 | 221.373 | 5.365.399 | |
| 2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 79.998 | 1.937.290 | 4,31 | 4,97 | 397.214 | 9.619.226 | |
| 2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 50.339 | 1.035.995 | 5,11 | 5,04 | 253.693 | 5.221.104 | |
| 2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 90.744 | 1.857.292 | 5,14 | 5,04 | 457.323 | 9.360.194 | |
| 2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 29.564 | 985.656 | 3,09 | 5,26 | 155.445 | 5.182.481 | |
| 2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 53.271 | 1.766.548 | 3,11 | 5,26 | 280.094 | 9.288.333 | |
| 2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 401.675 | 956.092 | 72,45 | 5,35 | 2.148.961 | 5.115.092 | |
| 2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 30.406 | 554.417 | 5,80 | 5,31 | 161.310 | 2.941.293 | |
| 2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 726.626 | 1.713.277 | 73,65 | 5,35 | 3.887.449 | 9.166.032 | |
| 2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 47.812 | 986.651 | 5,09 | 5,31 | 253.652 | 5.234.381 | |
| 2013-10-07 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 38.599 | 524.011 | 7,95 | 5,49 | 212.071 | 2.879.021 | |
| 2013-10-07 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 70.826 | 938.839 | 8,16 | 5,49 | 389.132 | 5.158.169 | |
| 2013-09-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -147.806 | 296.345 | -33,28 | 44,50 | -6.577.367 | 13.187.352 | |
| 2013-09-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -211.217 | 530.410 | -28,48 | 44,50 | -9.399.156 | 23.603.245 | |
| 2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 3.370 | 485.412 | 0,70 | 6,09 | 20.520 | 2.955.722 | |
| 2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 6.307 | 868.013 | 0,73 | 6,09 | 38.404 | 5.285.418 | |
| 2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 105.892 | 482.042 | 28,15 | 5,94 | 629.136 | 2.863.956 | |
| 2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 210.066 | 861.706 | 32,24 | 5,94 | 1.248.065 | 5.119.654 | |
| 2013-08-12 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 177.940 | 2.591.160 | 7,37 | 1,65 | 293.512 | 4.274.118 | |
| 2013-08-12 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 80.421 | 4.758.891 | 1,72 | 1,65 | 132.654 | 7.849.791 | |
| 2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 35.703 | 2.413.220 | 1,50 | 1,78 | 63.651 | 4.302.289 | |
| 2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 122.641 | 4.678.470 | 2,69 | 1,78 | 218.644 | 8.340.776 | |
| 2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 179.743 | 4.555.829 | 4,11 | 1,71 | 307.307 | 7.789.101 | |
| 2013-06-11 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 8.102 | 799.615 | 1,02 | 3,47 | 28.095 | 2.772.825 | |
| 2013-06-11 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 24.598 | 1.455.414 | 1,72 | 3,47 | 85.298 | 5.046.939 | |
| 2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 41.526 | 2.377.517 | 1,78 | 1,83 | 76.009 | 4.351.807 | |
| 2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 74.726 | 4.376.086 | 1,74 | 1,83 | 136.778 | 8.009.988 | |
| 2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 27.384 | 2.335.991 | 1,19 | 1,78 | 48.768 | 4.160.166 | |
| 2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 55.531 | 4.301.360 | 1,31 | 1,78 | 98.895 | 7.660.292 | |
| 2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 5.000 | 2.308.607 | 0,22 | 1,75 | 8.750 | 4.040.062 | |
| 2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 10.300 | 4.245.829 | 0,24 | 1,75 | 18.025 | 7.430.201 | |
| 2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
4.235.529 | ||||||||
| 2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
2.303.607 | ||||||||
| 2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
1.298.842 | ||||||||
| 2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
1.430.816 | ||||||||
| 2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
791.513 | ||||||||
| 2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
6.962.123 | ||||||||
| 2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
513.545 | ||||||||
| 2013-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 39.600 | 2.163.412 | 1,86 | 19,78 | 783.181 | 42.786.448 | |
| 2012-12-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 5.386 | 2.123.812 | 0,25 | 18,63 | 100.365 | 39.575.962 | |
| 2012-12-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 50.100 | 2.118.426 | 2,42 | 17,94 | 898.959 | 38.011.553 | |
| 2012-11-20 |
|
4/A | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 217.000 | 1.713.907 | 14,50 | 4,00 | 867.935 | 6.855.114 | |
| 2012-11-20 |
|
4/A | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 378.000 | 2.977.919 | 14,54 | 4,00 | 1.511.887 | 11.910.783 | |
| 2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 26.800 | 1.523.707 | 1,79 | 5,11 | 136.902 | 7.783.552 | |
| 2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 46.700 | 2.646.619 | 1,80 | 5,11 | 238.558 | 13.519.724 | |
| 2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 444.649 | 1.496.907 | 42,26 | 4,00 | 1.778.596 | 5.987.628 | |
| 2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 772.063 | 2.599.919 | 42,24 | 4,00 | 3.088.252 | 10.399.676 | |
| 2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
790.501 | ||||||||
| 2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
456.746 | ||||||||
| 2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
9.894.589 | ||||||||
| 2012-11-19 |
|
4/A | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 40.000 | 3.750.277 | 1,08 | 12,00 | 479.828 | 44.987.198 | |
| 2012-11-19 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.076 | 741.627 | 0,55 | 14,99 | 61.096 | 11.116.395 | |
| 2012-11-19 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12.515 | 737.551 | 1,73 | 15,26 | 190.926 | 11.251.931 | |
| 2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 17.400 | 1.052.258 | 1,68 | 4,01 | 69.718 | 4.216.187 | |
| 2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 31.929 | 1.827.856 | 1,78 | 4,01 | 127.933 | 7.323.853 | |
| 2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 8.800 | 1.034.858 | 0,86 | 4,08 | 35.915 | 4.223.462 | |
| 2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 14.300 | 1.795.927 | 0,80 | 4,08 | 58.361 | 7.329.537 | |
| 2012-11-08 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 40.000 | 3.750.277 | 1,08 | 12,00 | 479.828 | 44.987.198 | |
| 2012-11-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.076 | 741.627 | 0,55 | 14,99 | 61.096 | 11.116.395 | |
| 2012-11-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12.515 | 737.551 | 1,73 | 15,26 | 190.926 | 11.251.931 | |
| 2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 21.500 | 1.026.058 | 2,14 | 4,05 | 87.150 | 4.159.126 | |
| 2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 36.100 | 1.781.627 | 2,07 | 4,05 | 146.331 | 7.221.825 | |
| 2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
CommonStock |
P - Purchase | 23.400 | 1.004.558 | 2,38 | 4,05 | 94.688 | 4.064.944 | |
| 2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 6.700 | 1.745.527 | 0,39 | 4,05 | 27.112 | 7.063.275 | |
| 2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 5.300 | 981.158 | 0,54 | 4,06 | 21.495 | 3.979.283 | |
| 2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 46.700 | 1.738.827 | 2,76 | 4,06 | 189.401 | 7.052.161 | |
| 2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
1.692.127 | ||||||||
| 2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
975.858 | ||||||||
| 2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
349.482 | ||||||||
| 2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
651.640 | ||||||||
| 2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
376.150 | ||||||||
| 2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
3.710.277 |
